NORA520
/ Gerbera Therap
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
November 21, 2025
NuMom: A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
(clinicaltrials.gov)
- P2 | N=93 | Completed | Sponsor: DuKang Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed
Trial completion • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry
September 09, 2025
NuMom: A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
(clinicaltrials.gov)
- P2 | N=90 | Active, not recruiting | Sponsor: DuKang Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry
May 01, 2025
NuMom: A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
(clinicaltrials.gov)
- P2 | N=90 | Recruiting | Sponsor: DuKang Pharmaceuticals, Inc. | Trial completion date: Mar 2026 ➔ Dec 2025 | Trial primary completion date: Feb 2026 ➔ Nov 2025
Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry
July 12, 2024
NuMom: A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
(clinicaltrials.gov)
- P2 | N=90 | Recruiting | Sponsor: Gerbera Therapeutics, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry
February 29, 2024
NuMom: A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
(clinicaltrials.gov)
- P2 | N=90 | Not yet recruiting | Sponsor: Gerbera Therapeutics, Inc.
New P2 trial • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry
1 to 5
Of
5
Go to page
1